Gilead Sciences (GILD) Long-Term Investments (2009 - 2026)

Gilead Sciences has reported Long-Term Investments for 17 years, with the latest figure at $983.0 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments changed N/A year-over-year to $983.0 million; the trailing twelve-month figure through Mar 2026 stood at $983.0 million (changed N/A YoY), and the FY2025 full-year result was $3.0 billion, changed N/A from the prior year.
• Long-Term Investments for Q1 2026 stood at $983.0 million, down from $3.0 billion in the prior quarter.
• The five-year high for Long-Term Investments was $3.0 billion in Q4 2025, with the low at $983.0 million in Q1 2026.
• Historically, Long-Term Investments has averaged $1.5 billion across 4 years, with a median of $1.3 billion in 2023.
• Annual changes were most pronounced in 2022 — Long-Term Investments jumped 146.46% — and 2023, when it declined 9.83%.
• Gilead Sciences' Long-Term Investments stood at $1.2 billion in 2022, then slipped by 6.59% to $1.2 billion in 2023, then jumped by 155.72% to $3.0 billion in 2025, then sank by 66.95% to $983.0 million in 2026.
• The last three Long-Term Investments figures came in at $983.0 million (Q1 2026), $3.0 billion (Q4 2025), and $2.0 billion (Q3 2025), per Business Quant data.